We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Countdown to Hologic (HOLX) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Read MoreHide Full Article
The upcoming report from Hologic (HOLX - Free Report) is expected to reveal quarterly earnings of $1.02 per share, indicating an increase of 4.1% compared to the year-ago period. Analysts forecast revenues of $1.03 billion, representing an increase of 1.4% year over year.
The consensus EPS estimate for the quarter has undergone a downward revision of 0.8% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Hologic metrics that are commonly monitored and projected by Wall Street analysts.
According to the collective judgment of analysts, 'Revenue- Total Breast Health' should come in at $391.46 million. The estimate indicates a change of +3.6% from the prior-year quarter.
Analysts forecast 'Revenue- GYN Surgical' to reach $166.25 million. The estimate indicates a change of +2.5% from the prior-year quarter.
The consensus estimate for 'Revenue- Skeletal Health' stands at $14.97 million. The estimate suggests a change of -41.1% year over year.
The consensus among analysts is that 'Revenue- Total Diagnostics' will reach $455.29 million. The estimate points to a change of +1.7% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenues- Diagnostics- Cytology and Perinatal' of $122.37 million. The estimate points to a change of +2% from the year-ago quarter.
Analysts' assessment points toward 'Revenues- Breast Health- Breast Imaging' reaching $305.26 million. The estimate indicates a change of +1.3% from the prior-year quarter.
It is projected by analysts that the 'Revenues- Diagnostics- Blood Screening' will reach $4.99 million. The estimate indicates a change of -37.6% from the prior-year quarter.
Based on the collective assessment of analysts, 'Revenues- Diagnostics- Molecular Diagnostics' should arrive at $330.68 million. The estimate suggests a change of +3.4% year over year.
Analysts expect 'Revenues- Breast Health- Interventional Breast Solutions' to come in at $85.02 million. The estimate indicates a year-over-year change of +11.4%.
The average prediction of analysts places 'Revenues- Service and other revenue' at $191.73 million. The estimate suggests a change of +3.6% year over year.
Analysts predict that the 'Revenues- Product Sales' will reach $847.57 million. The estimate points to a change of +2.4% from the year-ago quarter.
Hologic shares have witnessed a change of +0.6% in the past month, in contrast to the Zacks S&P 500 composite's +2.9% move. With a Zacks Rank #3 (Hold), HOLX is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Countdown to Hologic (HOLX) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
The upcoming report from Hologic (HOLX - Free Report) is expected to reveal quarterly earnings of $1.02 per share, indicating an increase of 4.1% compared to the year-ago period. Analysts forecast revenues of $1.03 billion, representing an increase of 1.4% year over year.
The consensus EPS estimate for the quarter has undergone a downward revision of 0.8% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Hologic metrics that are commonly monitored and projected by Wall Street analysts.
According to the collective judgment of analysts, 'Revenue- Total Breast Health' should come in at $391.46 million. The estimate indicates a change of +3.6% from the prior-year quarter.
Analysts forecast 'Revenue- GYN Surgical' to reach $166.25 million. The estimate indicates a change of +2.5% from the prior-year quarter.
The consensus estimate for 'Revenue- Skeletal Health' stands at $14.97 million. The estimate suggests a change of -41.1% year over year.
The consensus among analysts is that 'Revenue- Total Diagnostics' will reach $455.29 million. The estimate points to a change of +1.7% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenues- Diagnostics- Cytology and Perinatal' of $122.37 million. The estimate points to a change of +2% from the year-ago quarter.
Analysts' assessment points toward 'Revenues- Breast Health- Breast Imaging' reaching $305.26 million. The estimate indicates a change of +1.3% from the prior-year quarter.
It is projected by analysts that the 'Revenues- Diagnostics- Blood Screening' will reach $4.99 million. The estimate indicates a change of -37.6% from the prior-year quarter.
Based on the collective assessment of analysts, 'Revenues- Diagnostics- Molecular Diagnostics' should arrive at $330.68 million. The estimate suggests a change of +3.4% year over year.
Analysts expect 'Revenues- Breast Health- Interventional Breast Solutions' to come in at $85.02 million. The estimate indicates a year-over-year change of +11.4%.
The average prediction of analysts places 'Revenues- Service and other revenue' at $191.73 million. The estimate suggests a change of +3.6% year over year.
Analysts predict that the 'Revenues- Product Sales' will reach $847.57 million. The estimate points to a change of +2.4% from the year-ago quarter.
View all Key Company Metrics for Hologic here>>>
Hologic shares have witnessed a change of +0.6% in the past month, in contrast to the Zacks S&P 500 composite's +2.9% move. With a Zacks Rank #3 (Hold), HOLX is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>